{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:41:16Z","timestamp":1792197676213,"version":"4.4.0"},"reference-count":65,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Matching patients with effective targeted therapies requires timely molecular results; however, the challenge today how to embed it into routine clinical workflows in ways that meaningfully affect patient-level treatment decisions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Building on prior work, the authors systematically reviewed laboratory operations, interdepartmental coordination, and administrative processes from two distinct healthcare settings: a US-based academic tertiary care center and a Canadian community hospital. We identified shared themes, context-specific challenges, and operational elements that distinguished successful integration from assay availability alone.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across both environments, the comparison revealed that rapid testing consistently accelerated treatment decisions and facilitated biomarker-informed patient management, but its successful implementation depended on re-engineering laboratory workflows, aligning personnel competencies, and establishing turnaround time monitoring; technical availability alone did not ensure clinically meaningful rapid testing. While the academic context integrated rapid testing within comprehensive molecular pipelines and research frameworks, the community hospital context focused on pragmatic adoption for frontline care, especially in urgent clinical settings and based on the organization of the Canadian health system.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Implementing rapid molecular testing in NSCLC is fundamentally an implementation and systems-engineering challenge rather than a technical challenge. Clinical speed depended more on system design than assay availability alone and is influenced, in part, by the larger national healthcare context. Addressing laboratory, operational, and administrative barriers is essential to ensure that rapid testing improves outcomes. Lessons learned from both academic and community practice provide a practical, implementation-focused roadmap for broader adoption and equity in access to precision oncology.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag388","type":"journal-article","created":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T11:56:17Z","timestamp":1790855777000},"source":"Crossref","is-referenced-by-count":0,"title":["Precision oncology at speed: workflow design determines clinical utility in rapid molecular testing for lung cancer"],"prefix":"10.1093","volume":"31","author":[{"given":"Brandon S","family":"Sheffield","sequence":"first","affiliation":[{"name":"Division of Advanced Diagnostics, William Osler Health System , Brampton, Ontario, L6R 3J7,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4740-9789","authenticated-orcid":false,"given":"Katherina","family":"Baranova","sequence":"additional","affiliation":[{"name":"Schulich School of Medicine and Dentistry , London, Ontario, N6G 2V4,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2666-3481","authenticated-orcid":false,"given":"Parneet","family":"Cheema","sequence":"additional","affiliation":[{"name":"University of Toronto , Toronto, Ontario, M5S 1A1,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam A","family":"Bredella","sequence":"additional","affiliation":[{"name":"NYU Langone Health, Grossman School of Medicine , New York, NY 10016,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Champica","family":"Nicholas","sequence":"additional","affiliation":[{"name":"Division of Advanced Diagnostics, William Osler Health System , Brampton, Ontario, L6R 3J7,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0781-9257","authenticated-orcid":false,"given":"Ibiayi","family":"Dagogo-Jack","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital , Cancer Center , Boston, MA 02114,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2434-4978","authenticated-orcid":false,"given":"Jochen K","family":"Lennerz","sequence":"additional","affiliation":[{"name":"Natera , Austin, Texas, 78753,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,10,1]]},"reference":[{"key":"2026101620070912000_oyag388-B1","doi-asserted-by":"crossref","first-page":"e389950","DOI":"10.1200\/EDBK_389950","article-title":"Treatment decisions for resectable non-small-cell lung cancer: balancing less with more?","volume":"43","author":"O\u2019Reilly","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"2026101620070912000_oyag388-B2","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"2026101620070912000_oyag388-B3","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1200\/JCO.2012.42.9829","article-title":"New targetable oncogenes in non-small-cell lung cancer","volume":"31","author":"Oxnard","year":"2013","journal-title":"J Clin Oncol"},{"key":"2026101620070912000_oyag388-B4","author":"NCCN Guideline","year":"2025"},{"key":"2026101620070912000_oyag388-B5","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/j.annonc.2020.07.014","article-title":"Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group","volume":"31","author":"Mosele","year":"2020","journal-title":"Ann Oncol"},{"key":"2026101620070912000_oyag388-B6","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00428-023-03702-7","article-title":"Molecular diagnostics tailoring personalized cancer therapy-an oncologist\u2019s view","volume":"484","author":"Riedl","year":"2024","journal-title":"Virchows Arch"},{"key":"2026101620070912000_oyag388-B7","doi-asserted-by":"crossref","first-page":"104245","DOI":"10.1016\/j.labinv.2025.104245","article-title":"Ultrarapid EGFR testing in non-small cell lung carcinoma patients: findings from a Canadian clinical testing workflow","volume":"105","author":"Fitzsimmons","year":"2025","journal-title":"Lab Invest"},{"key":"2026101620070912000_oyag388-B8","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.3390\/cancers16142505","article-title":"Point of care liquid biopsy for cancer treatment-early experience from a community center","volume":"16","author":"Nicholas","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026101620070912000_oyag388-B9","first-page":"PO.17.00299","article-title":"Clinical utility of rapid EGFR genotyping in advanced lung cancer","volume":"2018","author":"Dagogo-Jack","year":"2018","journal-title":"JCO Precis Oncol."},{"key":"2026101620070912000_oyag388-B10","doi-asserted-by":"crossref","first-page":"e349","DOI":"10.1016\/j.cllc.2017.03.001","article-title":"Molecular testing turnaround time for non-small cell lung cancer in routine clinical practice confirms feasibility of CAP\/IASLC\/AMP guideline recommendations: a single-center analysis","volume":"18","author":"DiStasio","year":"2017","journal-title":"Clin Lung Cancer"},{"key":"2026101620070912000_oyag388-B11","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1093\/oncolo\/oyac134","article-title":"Implementation and clinical adoption of precision oncology workflows across a healthcare network","volume":"27","author":"Dias-Santagata","year":"2022","journal-title":"Oncologist"},{"key":"2026101620070912000_oyag388-B12","doi-asserted-by":"crossref","first-page":"101628","DOI":"10.1016\/j.esmoop.2023.101628","article-title":"Real-world EGFR testing practices for non-small-cell lung cancer by thoracic pathology laboratories across Europe","volume":"8","author":"Hofman","year":"2023","journal-title":"ESMO Open"},{"key":"2026101620070912000_oyag388-B13","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1093\/oncolo\/oyad020","article-title":"Implementation of precision oncology in clinical practice: results of a national survey for health care professionals","volume":"28","author":"Fasola","year":"2023","journal-title":"Oncologist"},{"key":"2026101620070912000_oyag388-B14","doi-asserted-by":"crossref","first-page":"e2347700","DOI":"10.1001\/jamanetworkopen.2023.47700","article-title":"Biomarker testing in patients with unresectable advanced or recurrent non-small cell lung cancer","volume":"6","author":"Sakamoto","year":"2023","journal-title":"JAMA Netw Open"},{"key":"2026101620070912000_oyag388-B15","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1007\/s10555-024-10187-6","article-title":"Healthcare disparities, screening, and molecular testing in the changing landscape of non-small cell lung cancer in the United States: a review","volume":"43","author":"Kurzrock","year":"2024","journal-title":"Cancer Metastasis Rev"},{"key":"2026101620070912000_oyag388-B16","doi-asserted-by":"crossref","first-page":"e2200246","DOI":"10.1200\/PO.22.00246","article-title":"Impact of clinical practice gaps on the implementation of personalized medicine in advanced non-small-cell lung cancer","volume":"6","author":"Sadik","year":"2022","journal-title":"JCO Precis Oncol."},{"key":"2026101620070912000_oyag388-B17","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.cllc.2022.11.002","article-title":"Implementation challenges and disparities in molecular testing for patients with stage IV NSCLC: perspectives from an urban safety-net hospital","volume":"24","author":"Burns","year":"2023","journal-title":"Clin Lung Cancer"},{"key":"2026101620070912000_oyag388-B18","doi-asserted-by":"crossref","first-page":"e2300191","DOI":"10.1200\/PO.23.00191","article-title":"Association between availability of molecular genotyping results and overall survival in patients with advanced nonsquamous non-small-cell lung cancer","volume":"7","author":"Aggarwal","year":"2023","journal-title":"JCO Precis Oncol."},{"key":"2026101620070912000_oyag388-B19","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1377\/hlthaff.2017.1575","article-title":"Strategies for clinical implementation: precision oncology at three distinct institutions","volume":"37","author":"Nadauld","year":"2018","journal-title":"Health Aff (Millwood)"},{"key":"2026101620070912000_oyag388-B20","first-page":"1029","article-title":"Clinical harm from failure to deploy personalized medicine for patients with metastatic non\u2013small cell lung cancer","volume":"32","author":"Migliaccio-Walle","year":"2026","journal-title":"J Manag Care Spec Pharm"},{"key":"2026101620070912000_oyag388-B21","doi-asserted-by":"crossref","first-page":"OP2501191","DOI":"10.1200\/OP-25-01191","article-title":"Turnaround time of comprehensive genomic profiling in lung cancer and other solid tumors","author":"Fox","year":"2026","journal-title":"JCO Oncol Pract"},{"key":"2026101620070912000_oyag388-B22","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jtho.2018.12.032","article-title":"Expediting comprehensive molecular analysis to optimize initial treatment of lung cancer patients with minimal smoking history","volume":"14","author":"Dagogo-Jack","year":"2019","journal-title":"J Thorac Oncol"},{"key":"2026101620070912000_oyag388-B23","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1200\/OP.23.00031","article-title":"Integrated radiology, pathology, and pharmacy program to accelerate access to osimertinib","volume":"19","author":"Dagogo-Jack","year":"2023","journal-title":"JCO Oncol Pract"},{"key":"2026101620070912000_oyag388-B24","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.3390\/curroncol29030113","article-title":"Point of care molecular testing: community-based rapid next-generation sequencing to support cancer care","volume":"29","author":"Sheffield","year":"2022","journal-title":"Curr Oncol"},{"key":"2026101620070912000_oyag388-B25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.5858\/arpa.2017-0388-CP","article-title":"Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the college of American pathologists, the international association for the study of lung cancer, and the association for molecular pathology","volume":"142","author":"Lindeman","year":"2018","journal-title":"Arch Pathol Lab Med"},{"key":"2026101620070912000_oyag388-B26","first-page":"1802","article-title":"Clinical impact of rapid biomarker testing in non-small cell lung cancer in a community setting","volume":"1","author":"Matthews","year":"2020","journal-title":"Lab Invest"},{"key":"2026101620070912000_oyag388-B27","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.3390\/curroncol31030115","article-title":"Biomarker turnaround times and impact on treatment decisions in patients with advanced non-small cell lung carcinoma at a large Canadian community hospital with an affiliated regional cancer centre","volume":"31","author":"Fleming","year":"2024","journal-title":"Curr Oncol"},{"key":"2026101620070912000_oyag388-B28","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1200\/JOP.2016.014019","article-title":"Impact of reflex EGFR\/ ALK testing on time to treatment of patients with advanced nonsquamous non-small-cell lung cancer","volume":"13","author":"Cheema","year":"2017","journal-title":"J Oncol Pract"},{"key":"2026101620070912000_oyag388-B29","first-page":"100837","article-title":"Novel approach to proficiency testing reveals significant variations in biomarker practice leading to critical differences in lung cancer management","volume":"6","author":"Bisson","year":"2025","journal-title":"JTO Clin Res Rep"},{"key":"2026101620070912000_oyag388-B30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/jmp5010001","article-title":"Novel approach to proficiency testing highlights key practice variations in cancer biomarker delivery","volume":"5","author":"Bisson","year":"2024","journal-title":"JMP"},{"key":"2026101620070912000_oyag388-B31","doi-asserted-by":"crossref","first-page":"e6886","DOI":"10.1002\/cam4.6886","article-title":"Referred molecular testing as a barrier to optimal treatment decision making in metastatic non-small cell lung cancer: experience at a tertiary academic institution in Canada","volume":"13","author":"Grafham","year":"2024","journal-title":"Cancer Med"},{"key":"2026101620070912000_oyag388-B32","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jtho.2020.03.019","article-title":"Personalized diagnostic workflows: the next wave of precision medicine in NSCLC","volume":"15","author":"Dagogo-Jack","year":"2020","journal-title":"J Thorac Oncol"},{"key":"2026101620070912000_oyag388-B33","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.3390\/curroncol30020180","article-title":"Cost savings of expedited care with upfront next-generation sequencing testing versus single-gene testing among patients with metastatic non-small cell lung cancer based on current Canadian practices","volume":"30","author":"Sheffield","year":"2023","journal-title":"Curr Oncol"},{"key":"2026101620070912000_oyag388-B34","first-page":"68","article-title":"Evaluation of three automated extraction systems for the detection of SARS-CoV-2 from clinical respiratory specimens","volume":"12","author":"Lim","year":"2022","journal-title":"Life (Basel)"},{"key":"2026101620070912000_oyag388-B35","doi-asserted-by":"crossref","first-page":"102753","DOI":"10.1016\/j.fsigen.2022.102753","article-title":"Ion torrent TM genexus TM integrated sequencer and ForeNGS analysis software-an automatic NGS-STR workflow from DNA to profile for forensic science","volume":"61","author":"Guo","year":"2022","journal-title":"Forensic Sci Int Genet"},{"key":"2026101620070912000_oyag388-B36","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.3390\/microorganisms12122417","article-title":"A comparison of three automated nucleic acid extraction systems for human stool samples","volume":"12","author":"Kwa","year":"2024","journal-title":"Microorganisms"},{"key":"2026101620070912000_oyag388-B37","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.3390\/cancers14092258","article-title":"Setting up an ultra-fast next-generation sequencing approach as reflex testing at diagnosis of non-squamous non-small cell lung cancer; experience of a single center (LPCE, nice, France)","volume":"14","author":"Ili\u00e9","year":"2022","journal-title":"Cancers (Basel)"},{"key":"2026101620070912000_oyag388-B38","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.chest.2025.07.4095","article-title":"Implementing a precision medicine thoracic service using in-house reflex testing in a large academic-community practice","volume":"169","author":"Bruno","year":"2026","journal-title":"Chest"},{"key":"2026101620070912000_oyag388-B39","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1136\/jclinpath-2021-207987","article-title":"Integration of rapid PCR testing as an adjunct to NGS in diagnostic pathology services within the UK: evidence from a case series of non-squamous, non-small cell lung cancer (NSCLC) patients with follow-up","volume":"76","author":"Finall","year":"2023","journal-title":"J Clin Pathol"},{"key":"2026101620070912000_oyag388-B40","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jtho.2024.12.011","article-title":"LIBELULE: a randomized phase III study to evaluate the clinical relevance of early liquid biopsy in patients with suspicious metastatic lung cancer","volume":"20","author":"Swalduz","year":"2025","journal-title":"J Thorac Oncol"},{"key":"2026101620070912000_oyag388-B41","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.1002\/cncr.34628","article-title":"The American cancer society national lung cancer roundtable strategic plan: advancing comprehensive biomarker testing in non-small cell lung cancer","volume":"130","author":"Fox","year":"2024","journal-title":"Cancer"},{"key":"2026101620070912000_oyag388-B42","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.62438\/tunismed.v103i10.6140","article-title":"A decade of non-small cell lung cancer management: threats and opportunities in resource-limited setting","volume":"103","author":"Mejri","year":"2025","journal-title":"Tunis Med"},{"key":"2026101620070912000_oyag388-B43","first-page":"358","article-title":"Acquiring tissue for advanced lung cancer diagnosis and comprehensive biomarker testing: a national lung cancer roundtable best-practice guide","volume":"73","author":"Fox","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"2026101620070912000_oyag388-B44","doi-asserted-by":"crossref","first-page":"101587","DOI":"10.1016\/j.esmoop.2023.101587","article-title":"Pathologist-initiated reflex testing for biomarkers in non-small-cell lung cancer: expert consensus on the rationale and considerations for implementation","volume":"8","author":"Gosney","year":"2023","journal-title":"ESMO Open"},{"key":"2026101620070912000_oyag388-B45","doi-asserted-by":"crossref","first-page":"4200","DOI":"10.1002\/cncr.34926","article-title":"The American cancer society national lung cancer roundtable strategic plan: methods for improving turnaround time of comprehensive biomarker testing in non-small cell lung cancer","volume":"130","author":"Roy-Chowdhuri","year":"2024","journal-title":"Cancer"},{"key":"2026101620070912000_oyag388-B46","doi-asserted-by":"crossref","first-page":"e240335","DOI":"10.1148\/radiol.240335","article-title":"Administrative alignment for integrated diagnostics leads to shortened time to diagnose and service optimization","volume":"312","author":"Bredella","year":"2024","journal-title":"Radiology"},{"key":"2026101620070912000_oyag388-B47","first-page":"601","article-title":"Effect of a collaboration between a health plan, oncology practice, and comprehensive genomic profiling company from the payer perspective","volume":"25","author":"Reitsma","year":"2019","journal-title":"J Manag Care Spec Pharm"},{"key":"2026101620070912000_oyag388-B48","first-page":"PO.18.00074","article-title":"Estimated cost of anticancer therapy directed by comprehensive genomic profiling in a single-center study","volume":"2","author":"Chawla","year":"2018","journal-title":"JCO Precis Oncol."},{"key":"2026101620070912000_oyag388-B49","doi-asserted-by":"crossref","first-page":"505","DOI":"10.2217\/fon-2021-1040","article-title":"Diagnostic and economic value of biomarker testing for targetable mutations in non-small-cell lung cancer: a literature review","volume":"18","author":"Zheng","year":"2022","journal-title":"Future Oncol"},{"key":"2026101620070912000_oyag388-B50","doi-asserted-by":"crossref","first-page":"e29272","DOI":"10.1016\/j.heliyon.2024.e29272","article-title":"Economic assessment of NGS testing workflow for NSCLC in a healthcare setting","volume":"10","author":"Seminati","year":"2024","journal-title":"Heliyon"},{"key":"2026101620070912000_oyag388-B51","doi-asserted-by":"crossref","first-page":"e1803","DOI":"10.1002\/onco.13532","article-title":"Attrition of patients on a precision oncology trial: analysis of the I-PREDICT experience","volume":"25","author":"Bohan","year":"2020","journal-title":"Oncologist"},{"key":"2026101620070912000_oyag388-B52","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"2026101620070912000_oyag388-B53","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/cam4.4459","article-title":"Defining comprehensive biomarker-related testing and treatment practices for advanced non-small-cell lung cancer: results of a survey of U.S. oncologists","volume":"11","author":"Mileham","year":"2022","journal-title":"Cancer Med"},{"key":"2026101620070912000_oyag388-B54","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/jcp-2026-210826","article-title":"Adapt or become irrelevant: the pathologist as the new diagnostic architect","volume":"79","author":"de Socarraz","year":"2026","journal-title":"J Clin Pathol"},{"key":"2026101620070912000_oyag388-B55","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.lungcan.2022.08.003","article-title":"Optimising tissue acquisition and the molecular testing pathway for patients with non-small cell lung cancer: a UK expert consensus statement","volume":"172","author":"Navani","year":"2022","journal-title":"Lung Cancer"},{"key":"2026101620070912000_oyag388-B56","doi-asserted-by":"crossref","first-page":"17588359221126151","DOI":"10.1177\/17588359221126151","article-title":"Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy","volume":"14","author":"Garcia-Pardo","year":"2022","journal-title":"Ther Adv Med Oncol"},{"key":"2026101620070912000_oyag388-B57","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1002\/dc.25011","article-title":"Fast investigative lung cancer pathway and endobronchial ultrasound procedure supported by rapid on-site evaluation","volume":"50","author":"Khan","year":"2022","journal-title":"Diagn Cytopathol"},{"key":"2026101620070912000_oyag388-B58","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1093\/annonc\/mdv208","article-title":"Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer","volume":"26","author":"Lim","year":"2015","journal-title":"Ann Oncol"},{"key":"2026101620070912000_oyag388-B59","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.3390\/cancers16213654","article-title":"The impact of next-generation sequencing workflows on outcomes in advanced lung cancer: a retrospective analysis at one academic health system","volume":"16","author":"Vakkalagadda","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026101620070912000_oyag388-B60","doi-asserted-by":"crossref","first-page":"286","DOI":"10.21037\/tlcr.2019.04.14","article-title":"Molecular testing strategies in non-small cell lung cancer: optimizing the diagnostic journey","volume":"8","author":"Gregg","year":"2019","journal-title":"Transl Lung Cancer Res"},{"key":"2026101620070912000_oyag388-B61","doi-asserted-by":"crossref","first-page":"oyae357","DOI":"10.1093\/oncolo\/oyae357","article-title":"Emerging molecular testing paradigms in non-small cell lung cancer management-current perspectives and recommendations","volume":"30","author":"Penault-Llorca","year":"2025","journal-title":"Oncologist"},{"key":"2026101620070912000_oyag388-B62","doi-asserted-by":"crossref","first-page":"e1131","DOI":"10.1200\/OP.20.00612","article-title":"Relative impact of anticancer therapy on unplanned hospital care in patients with non\u2013small-cell lung cancer","volume":"17","author":"Shah","year":"2021","journal-title":"JCO Oncol Pract"},{"key":"2026101620070912000_oyag388-B63","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2025.927","article-title":"Biomarker testing practices for non-small cell lung cancer: survey insights from South Korean pathology laboratories","author":"Kim","year":"2026","journal-title":"Cancer Res Treat"},{"key":"2026101620070912000_oyag388-B64","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1093\/ajcp\/aqaf107","article-title":"Implementation of a next-generation sequencing and PD-L1 immunohistochemistry reflex testing protocol for non-small cell lung cancers improves turnaround time","volume":"164","author":"Major","year":"2025","journal-title":"Am J Clin Pathol"},{"key":"2026101620070912000_oyag388-B65","first-page":"41","article-title":"Rapidly fatal advanced EGFR-mutated lung cancers and the need for rapid tumor genotyping in clinical practice","volume":"9","author":"Rangachari","year":"2016","journal-title":"Cancer Treat Commun"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag388\/71561532\/oyag388.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/11\/oyag388\/71561532\/oyag388.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/11\/oyag388\/71561532\/oyag388.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:07:23Z","timestamp":1792195643000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag388\/8859276"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,1]]},"references-count":65,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,10,7]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag388","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,10,1]]},"article-number":"oyag388"}}